Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX NASDAQ:NEPH NASDAQ:NTRB NASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$2.99$3.65$1.26▼$46.50$11.03M2.84686,354 shs991,359 shsNEPHNephros$3.40$3.37$2.66▼$6.42$36.92M1.4910,479 shs25,575 shsNTRBNutriband$3.06$3.48$2.90▼$10.65$37.21M1.9312,687 shs11,387 shsSTRRStar Equity$11.15+1.5%$10.68$8.26▼$11.99$41.26M0.519,024 shs1,495 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics0.00%-2.29%-46.89%+94.79%-65.27%NEPHNephros0.00%-5.82%-0.58%+18.88%-16.67%NTRBNutriband0.00%0.00%-14.53%-17.96%-68.53%STRRStar Equity0.00%+1.92%-1.33%+15.07%+471.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$2.99$3.65$1.26▼$46.50$11.03M2.84686,354 shs991,359 shsNEPHNephros$3.40$3.37$2.66▼$6.42$36.92M1.4910,479 shs25,575 shsNTRBNutriband$3.06$3.48$2.90▼$10.65$37.21M1.9312,687 shs11,387 shsSTRRStar Equity$11.15+1.5%$10.68$8.26▼$11.99$41.26M0.519,024 shs1,495 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics0.00%-2.29%-46.89%+94.79%-65.27%NEPHNephros0.00%-5.82%-0.58%+18.88%-16.67%NTRBNutriband0.00%0.00%-14.53%-17.96%-68.53%STRRStar Equity0.00%+1.92%-1.33%+15.07%+471.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 2.00Hold$67.502,157.53% UpsideNEPHNephros 2.50Moderate Buy$6.0076.47% UpsideNTRBNutriband 1.50ReduceN/AN/ASTRRStar Equity 2.20Hold$28.00151.12% UpsideCurrent Analyst Ratings BreakdownLatest CODX, STRR, NTRB, and NEPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/18/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/17/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/3/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/20/2026STRRStar Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026STRRStar Equity Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$620K17.80N/AN/A$9.14 per share0.33NEPHNephros$18.79M1.97$0.13 per share27.10$0.96 per share3.54NTRBNutriband$2.04M18.24N/AN/A$0.55 per share5.56STRRStar Equity$172.16M0.24$0.64 per share17.34$19.12 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)NEPHNephros$1.19M$0.0748.58N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)NTRBNutriband-$8.23M-$2.58N/AN/AN/A-448.25%-112.64%-97.86%N/ASTRRStar Equity-$5.92M-$2.63N/A10.72N/A-4.18%-4.04%-2.40%8/6/2026 (Estimated)Latest CODX, STRR, NTRB, and NEPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q1 2027NTRBNutribandN/A-$0.10N/A-$0.10N/A$0.43 million5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/11/2026Q1 2026STRRStar Equity$0.05-$0.99-$1.04-$1.17$52.57 million$50.06 million5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A2.282.09NEPHNephrosN/A4.553.12NTRBNutribandN/A5.265.11STRRStar Equity0.092.091.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%NEPHNephros41.10%NTRBNutriband19.70%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics5.40%NEPHNephros6.70%NTRBNutriband52.21%STRRStar Equity31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableNEPHNephros3010.86 million10.13 millionNot OptionableNTRBNutriband1012.16 million5.81 millionNot OptionableSTRRStar Equity1,2003.70 million2.53 millionNot OptionableCODX, STRR, NTRB, and NEPH HeadlinesRecent News About These CompaniesStar Equity Holdings Added to the Russell Microcap® IndexJune 29, 2026 | globenewswire.comInsider Buying: Star Equity (NASDAQ:STRR) CEO Acquires 4,766 Shares of StockJune 24, 2026 | insidertrades.comJeffrey Eberwein Acquires 4,994 Shares of Star Equity (NASDAQ:STRR) StockJune 18, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Jeffrey Eberwein Purchases 1,884 SharesJune 13, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Jeffrey Eberwein Purchases 2,849 SharesJune 10, 2026 | insidertrades.comJeffrey Eberwein Purchases 1,430 Shares of Star Equity (NASDAQ:STRR) StockJune 5, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) Director Acquires $11,600.00 in StockJune 3, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Acquires $17,176.38 in StockJune 2, 2026 | insidertrades.comStar Equity Holdings, Inc. to Present at Noble Capital Markets Emerging Growth Virtual Conference on June 3-4, 2026June 1, 2026 | quiverquant.comQStar Equity Holdings to Present at the Noble Capital Markets Emerging Growth Virtual Conference on June 3-4June 1, 2026 | globenewswire.comStar Equity (NASDAQ:STRR) CEO Buys $26,906.88 in StockMay 28, 2026 | insidertrades.comInsider Stock Buying Reaches US$4.21m On Star Equity HoldingsMay 22, 2026 | finance.yahoo.comInsider Buying: Star Equity (NASDAQ:STRR) CEO Buys 4,198 Shares of StockMay 22, 2026 | insidertrades.comStar Equity Launches ATM Preferred Stock Offering ProgramMay 18, 2026 | tipranks.comStar Equity Declares Cash Dividend on Preferred StockMay 15, 2026 | tipranks.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred StockMay 15, 2026 | globenewswire.comStar Equity Holdings: Q1 Earnings SnapshotMay 11, 2026 | khou.comKStar Equity Holdings (STRR) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2026 | zacks.comStar Equity Holdings Reports Strong Q1 Revenue Growth and Achieves $2.6 Million in Merger SynergiesMay 11, 2026 | quiverquant.comQStar Equity Holdings Reports 2026 First Quarter ResultsMay 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, STRR, NTRB, and NEPH Company DescriptionsCo-Diagnostics NASDAQ:CODX$2.99 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.10 +0.11 (+3.51%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Nephros NASDAQ:NEPH$3.40 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$3.52 +0.12 (+3.56%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Nutriband NASDAQ:NTRB$3.06 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$3.04 -0.02 (-0.65%) As of 07/2/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Star Equity NASDAQ:STRR$11.15 +0.16 (+1.46%) Closing price 07/2/2026 03:58 PM EasternExtended Trading$11.08 -0.07 (-0.66%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
